KR900017612A - 생물학적 반응 변경인자용 항체 수송 시스템 - Google Patents

생물학적 반응 변경인자용 항체 수송 시스템 Download PDF

Info

Publication number
KR900017612A
KR900017612A KR1019900006320A KR900006320A KR900017612A KR 900017612 A KR900017612 A KR 900017612A KR 1019900006320 A KR1019900006320 A KR 1019900006320A KR 900006320 A KR900006320 A KR 900006320A KR 900017612 A KR900017612 A KR 900017612A
Authority
KR
South Korea
Prior art keywords
composition
antibody
biological response
tnf
administering
Prior art date
Application number
KR1019900006320A
Other languages
English (en)
Other versions
KR0181294B1 (ko
Inventor
지. 로젠블럼 마이클
윌리엄 웰렌 클라이드
Original Assignee
제임스 에프. 웨일러
리써치 디벨로프먼트 화운데이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 제임스 에프. 웨일러, 리써치 디벨로프먼트 화운데이션 filed Critical 제임스 에프. 웨일러
Publication of KR900017612A publication Critical patent/KR900017612A/ko
Application granted granted Critical
Publication of KR0181294B1 publication Critical patent/KR0181294B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

내용 없음

Description

생물학적 반응 변경인자용 항체 수송 시스템
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 ZME-TNF반응 혼합물의 S-300겔 투과 크로마토 그래피 결과도이다. 제2도는 S-300 크로마트그래피하여 수집한 분획의 친화성 크로마토그래피를 한 후의 크로마토그래피 개략도이다. 제3도는 표적 항원 양성 A-375세포 및 항원 음성 T-24세포에 대한 ZME-018-TNF접합체 및 유리 TNF의 결합 비교도이다.

Claims (22)

  1. 종양 관련 항원에 대한 항체와 생물학적 반응 변경인자 잔기의 접합체를 함유함을 특징으로 하는조성물.
  2. 제1항에 있어서, 조성물이 항체 잔기와 생물학적 반응 변경인자를 함유하는 재조합적으로 생성된 화합물인 조성물.
  3. 제1항에 있어서, 잔기가 세포독성이 있는 조성물.
  4. 제1항에 있어서, 잔기가 종양 괴사인자, IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, TNF-α, TNF-β,IFN-α,IFN-β,IFN-入로 이루어진 그룹중에서 선택되는 조성물.
  5. 제1항에 있어서,잔기가 종양 괴사 인자인 조성물.
  6. 제1항에 있어서, 항체가 유방암 항원에 대한 항체인 방법.
  7. 제6항에 있어서, 항체가15A8항체의 특성을 갖는조성물.
  8. 제1항에 있어서, 항체가 흑색종 항원에 대한 특성을 갖는 조성물.
  9. 제8항에 있어서, 항체가 ZME-018항체의 특성을 갖는 조성물.
  10. 살세포 유효용량의 제1항에 따른 조성물을 치료를 요하는 개체에 투여함을 특징으로 하여, 증식성 세포질환을 치료하는 방법.
  11. 제10항에 있어서, 증식성 세포질환이 암인 방법.
  12. 제11항에 있어서, 암이 유방암, 경부암 및 흑색종으로 이루어진 그룹중에서 선택되는 방법.
  13. 15A8항원에 대한 TNF-접합된 모노클로날 항체를 치료를 요하는 개체에 투여함을 특징으로 하여, 유방압을 치료하는 방법.
  14. 15A8종양 관련 항원에 대한 세포독성 용량 또는 정균 용량의 TNF-접합된 모노클로날 항체를 치료를 요하는 개체에 투여함을 특징으로 하여, 경부암을 치료하는 방법.
  15. 세포독성 용량 또는 정균 용량의 TNF-접합된 모노클로날 항체 15A8을 15A8종양 관련 항원을 함유하는 종양에 걸린 것으로 진단된 개체에 투여함을 특징으로 하여, 사람의 유방암을 치료하는 방법.
  16. TNF-접합된 모노클로날 항체 15A8을 치료를 요하는 개체에 투여함을 특징으로 하여, 종양의 재발을 예방하는 방법.
  17. TNF-접합된 모노클로날 항체ZME-018를 치료를 요하는 개체에 투여함을 특징으로 하여, 흑색종을 치료하는 방법.
  18. 종양 관련 항원에 대한 항체와 생물학적 반응 변경인자 잔기의 접합체 및 사람의 인터페론을 함유함을 특징으로 하는 조성물.
  19. 제1항에 있어서, 접합체가 모노클로날 항체의 항원 인지부위-암호화 유전자와 생물학적 반응 변경인자-암호화 유전자의 융합에 의하여 재조합적으로 생성된 유전자-융합 생성물인 조성물.
  20. 제19항에 있어서, 생물학적 반응 변경인자가 림포카인 및 사이토카인으로 이루어진 그룹중에서 선택된 조성물.
  21. 제19항에 있어서, 생물학적 반응 변경인자가 종양 괴사 인자인 조성물.
  22. 수정체를 외과수술로 대치한 후 제1항에 따른 면역접합체를 개체에 투여함을 특징으로 하여, 2차백내장 형성을 억제시키는 방법.
    ※ 참고사항 : 최초출원내용에 의하여 공개하는 것임.
KR1019900006320A 1989-05-05 1990-05-04 생물학적 반응 변경인자용 항체 수송 시스템 KR0181294B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34823789A 1989-05-05 1989-05-05
US348,237 1989-05-05

Publications (2)

Publication Number Publication Date
KR900017612A true KR900017612A (ko) 1990-12-19
KR0181294B1 KR0181294B1 (ko) 1999-03-20

Family

ID=23367161

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019900006320A KR0181294B1 (ko) 1989-05-05 1990-05-04 생물학적 반응 변경인자용 항체 수송 시스템

Country Status (19)

Country Link
EP (1) EP0396387B1 (ko)
JP (1) JP3589459B2 (ko)
KR (1) KR0181294B1 (ko)
CN (1) CN1072505C (ko)
AT (1) ATE98873T1 (ko)
AU (1) AU645747B2 (ko)
CA (1) CA2015060C (ko)
DE (1) DE69005352T2 (ko)
DK (1) DK0396387T3 (ko)
ES (1) ES2060947T3 (ko)
FI (1) FI100092B (ko)
HK (1) HK1006678A1 (ko)
IE (1) IE63847B1 (ko)
IL (1) IL94167A (ko)
NO (1) NO301168B1 (ko)
NZ (1) NZ233413A (ko)
PT (1) PT93966B (ko)
SA (1) SA90110099B1 (ko)
ZA (1) ZA902949B (ko)

Families Citing this family (189)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0406857B1 (en) * 1989-07-07 1995-05-24 Takeda Chemical Industries, Ltd. Proteins and production thereof
US5314995A (en) * 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
CA2073964A1 (en) * 1990-02-06 1991-08-07 Naoru Hamaguchi Immune complexes
ZA912490B (en) * 1990-04-19 1992-12-30 Res Dev Foundation Antibody conjugates for treatment of neoplastic disease
US5349053A (en) * 1990-06-01 1994-09-20 Protein Design Labs, Inc. Chimeric ligand/immunoglobulin molecules and their uses
US5273889A (en) * 1990-08-22 1993-12-28 University Of Saskatchewan Gamma-iterferon-leukotoxin gene fusions and uses thereof
US5594107A (en) * 1990-08-22 1997-01-14 University Of Saskatchewan Chimeric protein comprising an RTX-family cytotoxin and interferon-2 or interferon
ES2171392T3 (es) * 1990-08-29 2002-09-16 Ct Hospitalier Regional De Nan Poliligandos de proteina unidos a un nucleo de proteina estable.
EP0556328A4 (en) * 1990-11-09 1994-06-08 Abbott Lab Bridging antibody fusion constructs
EP0574395B1 (en) * 1990-11-09 2002-06-12 GILLIES, Stephen D. Cytokine immunoconjugates
US5650150A (en) * 1990-11-09 1997-07-22 Gillies; Stephen D. Recombinant antibody cytokine fusion proteins
JPH06508821A (ja) * 1991-03-07 1994-10-06 セラジュン　インク ウイルス病治療のための細胞表面受容体を標的とする分子の使用
JP3105629B2 (ja) * 1991-04-23 2000-11-06 サングスタット メディカル コーポレイション 特異的結合ペアのメンバーの細胞活性調節接合体
US5326559A (en) * 1991-05-16 1994-07-05 Miller D Douglas Treatment of accelerated atheosclerosis with interleukin-2 receptor targeted molecules
ATE168014T1 (de) * 1991-11-08 1998-07-15 Somatogen Inc Hämoglobine als arzneimittelabgabesystem
GB9324807D0 (en) * 1993-12-03 1994-01-19 Cancer Res Campaign Tech Tumour antibody
DE69428764T2 (de) * 1993-12-24 2002-06-20 Merck Patent Gmbh Immunokonjugate
GB9415379D0 (en) * 1994-07-29 1994-09-21 Smithkline Beecham Plc Novel compounds
ES2167391T3 (es) * 1994-09-16 2002-05-16 Merck Patent Gmbh Inmunoconjugados ii.
US7820798B2 (en) 1994-11-07 2010-10-26 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
US7429646B1 (en) 1995-06-05 2008-09-30 Human Genome Sciences, Inc. Antibodies to human tumor necrosis factor receptor-like 2
US6090382A (en) * 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
US6482927B1 (en) * 1995-11-27 2002-11-19 Millennium Pharmaceuticals, Inc. Chimeric proteins comprising the extracellular domain of murine Ob receptor
US6620413B1 (en) 1995-12-27 2003-09-16 Genentech, Inc. OB protein-polymer chimeras
US7074397B1 (en) 1996-01-08 2006-07-11 Genentech, Inc. Method for enhancing proliferation or differentiation of a cell using ob protein
US6541604B1 (en) 1996-01-08 2003-04-01 Genentech, Inc. Leptin receptor having a WSX motif
US20050019325A1 (en) 1996-01-08 2005-01-27 Carter Paul J. WSX receptor agonist antibodies
US7888466B2 (en) 1996-01-11 2011-02-15 Human Genome Sciences, Inc. Human G-protein chemokine receptor HSATU68
HU230515B1 (hu) * 1996-02-09 2016-10-28 Abbvie Biotechnology Ltd Humán TNFalfa-kötő antitestek alkalmazásai
WO1999029732A2 (en) 1997-12-08 1999-06-17 Lexigen Pharmaceuticals Corporation Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation
EP1093457B8 (en) 1998-03-19 2011-02-02 Human Genome Sciences, Inc. Cytokine receptor common gamma chain like
AU3501700A (en) 1999-02-26 2000-09-14 Human Genome Sciences, Inc. Human endokine alpha and methods of use
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
EP1200479B1 (en) 1999-08-09 2006-02-01 Lexigen Pharmaceuticals Corp. Multiple cytokine-antibody complexes
WO2001058957A2 (en) 2000-02-11 2001-08-16 Lexigen Pharmaceuticals Corp. Enhancing the circulating half-life of antibody-based fusion proteins
US20030031675A1 (en) 2000-06-06 2003-02-13 Mikesell Glen E. B7-related nucleic acids and polypeptides useful for immunomodulation
EP2431054A3 (en) 2000-06-15 2013-03-06 Human Genome Sciences, Inc. Human tumor necrosis factor delta and epsilon
ES2609016T3 (es) 2000-06-16 2017-04-18 Human Genome Sciences, Inc. Anticuerpos que se unen inmunoespecíficamente a BLyS
JP2003535908A (ja) * 2000-06-22 2003-12-02 アイデック ファーマスーティカルズ コーポレイション 二重特異性融合タンパク及び標的細胞を殺傷するエフェクター細胞を増強するための使用方法
EP2338512A1 (en) 2000-11-28 2011-06-29 MedImmune, LLC Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
CN1564826A (zh) 2001-02-09 2005-01-12 人类基因组科学公司 人类g蛋白趋化因子受体(ccr5)hdgnr10
ZA200305980B (en) 2001-02-12 2007-01-31 Res Dev Foundation Modified proteins, designer toxins, and methods of making thereof
AU2002248571B2 (en) 2001-03-07 2007-01-18 Merck Patent Gmbh Expression technology for proteins containing a hybrid isotype antibody moiety
WO2002079415A2 (en) 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
DK1385864T3 (da) 2001-04-13 2010-08-16 Human Genome Sciences Inc Anti-VEGF-2-antistoffer
EP1383785B1 (en) 2001-05-03 2011-03-16 Merck Patent GmbH Recombinant tumor specific antibody and use thereof
KR100942393B1 (ko) 2001-05-25 2010-02-17 휴먼 게놈 사이언시즈, 인코포레이티드 Ｔｒａｉｌ 수용체에 면역특이적으로 결합하는 항체
US7101977B2 (en) 2001-07-17 2006-09-05 Research Development Foundation Therapeutic agents comprising pro-apoptotic proteins
US6867189B2 (en) 2001-07-26 2005-03-15 Genset S.A. Use of adipsin/complement factor D in the treatment of metabolic related disorders
AU2002357784B2 (en) 2001-12-04 2008-07-31 Merck Patent Gmbh Immunocytokines with modulated selectivity
CA2481747A1 (en) 2002-04-12 2003-10-23 Medimmune, Inc. Recombinant anti-interleukin-9 antibodies
GB0209896D0 (en) * 2002-04-30 2002-06-05 Molmed Spa Conjugate
AU2003274463B2 (en) 2002-06-10 2009-10-29 University Of Rochester Gene differentially expressed in breast and bladder cancer and encoded polypeptides
US7232888B2 (en) 2002-07-01 2007-06-19 Massachusetts Institute Of Technology Antibodies against tumor surface antigens
KR101086660B1 (ko) 2002-12-17 2011-11-24 메르크 파텐트 게엠베하 Ｇｄ2 에 결합하는 마우스 14.18 항체의 인간화 항체(ｈ14.18) 및 그것의 ｉｌ-2 와의 융합
SI2248899T1 (sl) 2003-03-19 2015-07-31 Biogen Ma Inc. Vezavni protein receptorja Nogo
EP2266628A3 (en) 2003-05-13 2012-01-18 Novartis Vaccines and Diagnostics, Inc. Method of determining the susceptibility to bone meatastases by EPhA2 expression
PT2805728T (pt) 2003-12-23 2020-04-08 Genentech Inc Novos anticorpos anti-il13 e o uso dos mesmos
PT1699822E (pt) 2003-12-30 2008-07-30 Merck Patent Gmbh Proteínas de fusão de il-7
AU2005203962C1 (en) 2004-01-05 2012-11-08 Antisoma Research Limited Interleukin-12 targeted to oncofoetal fibronectin
EP2474317A1 (en) 2004-06-24 2012-07-11 Biogen Idec MA Inc. Treatment of conditions involving demyelination
US7670595B2 (en) 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
US20080267981A1 (en) * 2004-06-30 2008-10-30 The Scripps Research Institute Compositions and Methods for Delivery of Antitumor Agents
EP2329714A1 (en) 2004-08-03 2011-06-08 Biogen Idec MA Inc. Influence of TAJ in the neuronal functions
US8165517B2 (en) 2005-01-19 2012-04-24 The Trustees Of The University Of Pennsylvania Methods for identifying inhibitors of vascular injury
KR20080025174A (ko) 2005-06-23 2008-03-19 메디뮨 인코포레이티드 응집 및 단편화 프로파일이 최적화된 항체 제제
WO2007008547A2 (en) 2005-07-08 2007-01-18 Biogen Idec Ma Inc. Sp35 antibodies and uses thereof
US7482124B2 (en) 2005-07-08 2009-01-27 Bristol-Myers Squibb Company Method of identifying a PPARgamma-agonist compound having a decreased likelihood of inducing dose-dependent peripheral edema
MY151064A (en) 2005-11-04 2014-03-31 Genentech Inc Use of complement pathway inhibitors to treat ocular diseases
US20090246189A1 (en) 2005-11-04 2009-10-01 Biogen Idec Ma Inc. And Mclean Hospital Methods for Promoting Neurite Outgrowth and Survival of Dopaminergic Neurons
ZA200804082B (en) 2005-11-07 2010-02-24 Scripps Research Inst Compositions and methods for controlling tissue factor signaling specificity
JP5312039B2 (ja) 2005-12-02 2013-10-09 バイオジェン・アイデック・エムエイ・インコーポレイテッド 脱髄の関与する状態の処置
CN103215293B (zh) 2006-01-27 2015-10-28 比奥根Ma公司 Nogo受体拮抗剂
JP2009541208A (ja) 2006-04-13 2009-11-26 ノバルティス・バクシーンズ・アンド・ダイアグノスティクス・インコーポレイテッド がんを処置し、診断しもしくは検出する方法
DK2044120T3 (da) 2006-06-07 2019-04-15 Bioalliance Cv Antistoffer, der genkender en kulhydratholdig epitop på cd-43 og cea eksprimeret på cancerceller, og fremgangsmåder til anvendelse deraf
US7572618B2 (en) 2006-06-30 2009-08-11 Bristol-Myers Squibb Company Polynucleotides encoding novel PCSK9 variants
DK2484696T3 (en) 2006-08-28 2017-10-02 Kyowa Hakko Kirin Co Ltd Antagonistic hLIGHT-specific human monoclonal antibodies
US9382327B2 (en) 2006-10-10 2016-07-05 Vaccinex, Inc. Anti-CD20 antibodies and methods of use
US7935791B2 (en) 2006-12-18 2011-05-03 Genentech, Inc. Antagonist anti-Notch3 antibodies and their use in the prevention and treatment of Notch3-related diseases
ES2635317T3 (es) 2007-01-05 2017-10-03 University Of Zurich Anticuerpo anti-beta-amiloide y sus usos
US8128926B2 (en) 2007-01-09 2012-03-06 Biogen Idec Ma Inc. Sp35 antibodies and uses thereof
EP2740744B1 (en) 2007-01-09 2018-03-28 Biogen MA Inc. Sp35 antibodies and uses thereof
NZ578816A (en) 2007-02-02 2012-06-29 Biogen Idec Inc Use of semaphorin 6a for promoting myelination and oligodendrocyte differentiation
JP2010521180A (ja) 2007-03-14 2010-06-24 ノバルティス アーゲー 癌を処置、診断または検出するためのａｐｃｄｄ１阻害剤
EP2599791A1 (en) 2007-04-27 2013-06-05 Genentech, Inc. Potent, stable and non-immunosuppressive anti-CD4 antibodies
US8647622B2 (en) 2007-08-29 2014-02-11 Sanofi Humanized anti-CXCR5 antibodies, derivatives thereof and their use
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
PT3002298T (pt) 2007-11-21 2019-11-20 Univ Oregon Health & Science Anticorpos monoclonais anti-fator xi e métodos de utilização dos mesmos
CA2706502C (en) 2007-12-18 2018-08-07 Bioalliance C.V. Antibodies recognizing a carbohydrate containing epitope on cd-43 and cea expressed on cancer cells and methods using same
KR101642846B1 (ko) 2007-12-26 2016-07-26 백시넥스 인코포레이티드 항-ｃ35 항체 병용 치료 및 방법
WO2009118300A1 (en) 2008-03-25 2009-10-01 Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Treating cancer by down-regulating frizzled-4 and/or frizzled-1
MX2010011206A (es) 2008-04-16 2010-11-12 Biogen Idec Inc Metodo para aislar biomacromoleculas usando glicol de polialquileno y metales de transicion.
US8058406B2 (en) 2008-07-09 2011-11-15 Biogen Idec Ma Inc. Composition comprising antibodies to LINGO or fragments thereof
CA2735433C (en) 2008-09-07 2016-02-16 Glyconex Inc. Anti-extended type i glycosphingolipid antibody, derivatives thereof and use
US8734795B2 (en) 2008-10-31 2014-05-27 Biogen Idec Ma Inc. Light targeting molecules and uses thereof
JP5810413B2 (ja) 2008-12-19 2015-11-11 バイオジェン インターナショナル ニューロサイエンス ゲーエムベーハー ヒト抗アルファシヌクレイン自己抗体
JP2012514458A (ja) 2008-12-31 2012-06-28 バイオジェン・アイデック・エムエイ・インコーポレイテッド 抗リンホトキシン抗体
WO2010100247A1 (en) 2009-03-06 2010-09-10 Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research Novel therapy for anxiety
US8524869B2 (en) 2009-03-24 2013-09-03 Teva Biopharmaceuticals Usa, Inc. Humanized antibodies against LIGHT and uses thereof
EP2241323A1 (en) 2009-04-14 2010-10-20 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Tenascin-W and brain cancers
MX2011011044A (es) 2009-04-22 2011-11-04 Merck Patent Gmbh Proteinas de fusion de anticuerpos con sitios de enlace de receptor fc neonatal (fcrn) modificados.
DK2427212T3 (en) 2009-05-08 2017-12-04 Vaccinex Inc ANTI-CD100 ANTIBODIES AND PROCEDURES FOR USE THEREOF
JP5762408B2 (ja) 2009-08-13 2015-08-12 クルセル ホランド ベー ヴェー ヒト呼吸器合胞体ウイルス（ｒｓｖ）に対する抗体および使用方法
EP2292266A1 (en) 2009-08-27 2011-03-09 Novartis Forschungsstiftung, Zweigniederlassung Treating cancer by modulating copine III
WO2011035205A2 (en) 2009-09-18 2011-03-24 Calmune Corporation Antibodies against candida, collections thereof and methods of use
EP2480573A1 (en) 2009-09-22 2012-08-01 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Treating cancer by modulating mex-3
WO2011045352A2 (en) 2009-10-15 2011-04-21 Novartis Forschungsstiftung Spleen tyrosine kinase and brain cancers
US20120213801A1 (en) 2009-10-30 2012-08-23 Ekaterina Gresko Phosphorylated Twist1 and cancer
EP2496600A1 (en) 2009-11-04 2012-09-12 Fabrus LLC Methods for affinity maturation-based antibody optimization
WO2011107586A1 (en) 2010-03-05 2011-09-09 Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research, Smoc1, tenascin-c and brain cancers
WO2011131611A1 (en) 2010-04-19 2011-10-27 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Modulating xrn1
WO2011154485A1 (en) 2010-06-10 2011-12-15 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Treating cancer by modulating mammalian sterile 20-like kinase 3
CN106188284B (zh) 2010-07-09 2020-05-08 扬森疫苗与预防公司 抗人呼吸道合胞病毒(rsv)抗体以及使用方法
EP2609431B1 (en) 2010-08-27 2017-05-10 University of Zurich Method for target and drug validation in inflammatory and/or cardiovascular diseases
WO2012031099A2 (en) 2010-09-02 2012-03-08 Vaccinex, Inc. Anti-cxcl13 antibodies and methods of using the same
WO2012032143A1 (en) 2010-09-10 2012-03-15 Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research Phosphorylated twist1 and metastasis
US20130295021A1 (en) 2010-10-11 2013-11-07 Feng Chen Human anti-tau antibodies
WO2012065937A1 (en) 2010-11-15 2012-05-24 Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research Anti-fungal agents
CN103380145B (zh) 2010-12-17 2016-10-12 生物控股有限公司 人类抗-sod1抗体
EP2686014A1 (en) 2011-03-16 2014-01-22 Sanofi Uses of a dual v region antibody-like protein
WO2012168259A1 (en) 2011-06-06 2012-12-13 Novartis Forschungsstiftung, Zweigniederlassung Protein tyrosine phosphatase, non-receptor type 11 (ptpn11) and triple-negative breast cancer
US9561274B2 (en) 2011-06-07 2017-02-07 University Of Hawaii Treatment and prevention of cancer with HMGB1 antagonists
US9244074B2 (en) 2011-06-07 2016-01-26 University Of Hawaii Biomarker of asbestos exposure and mesothelioma
MX357193B (es) 2011-06-23 2018-06-29 Univ Zuerich Moleculas de union anti-alfa sinucleina.
EP2753697A1 (en) 2011-09-05 2014-07-16 ETH Zürich Biosynthetic gene cluster for the production of peptide/protein analogues
WO2013039954A1 (en) 2011-09-14 2013-03-21 Sanofi Anti-gitr antibodies
JP2014533247A (ja) 2011-11-01 2014-12-11 バイオノミクス インコーポレイテッド 抗体および癌を治療する方法
WO2013067060A1 (en) 2011-11-01 2013-05-10 Bionomics, Inc. Anti-gpr49 antibodies
US9220774B2 (en) 2011-11-01 2015-12-29 Bionomics Inc. Methods of treating cancer by administering anti-GPR49 antibodies
ES2697674T3 (es) 2011-11-01 2019-01-25 Bionomics Inc Procedimientos para bloquear el crecimiento de células madre cancerosas
US20140314787A1 (en) 2011-11-08 2014-10-23 Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute Treatment for neurodegenerative diseases
WO2013068432A1 (en) 2011-11-08 2013-05-16 Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research Early diagnostic of neurodegenerative diseases
ES2784131T3 (es) 2011-12-05 2020-09-22 X Body Inc Polipéptidos de unión beta del receptor PDGF
EP2800583A1 (en) 2012-01-02 2014-11-12 Novartis AG Cdcp1 and breast cancer
CA2865928C (en) 2012-03-02 2021-02-16 Vaccinex, Inc. Cxcl13 antagonist for the treatment of sjogren's syndrome
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
JP6779012B2 (ja) 2012-03-28 2020-11-04 サノフイＳａｎｏｆｉ ブラジキニンｂ１受容体リガンドに対する抗体
WO2013144240A1 (en) 2012-03-29 2013-10-03 Friedrich Miescher Institute For Biomedical Research Inhibition of interleukin- 8 and/or its receptor cxcrl in the treatment her2/her3 -overexpressing breast cancer
SG11201407209YA (en) 2012-05-07 2014-12-30 Sanofi Sa Methods for preventing biofilm formation
CA2873623C (en) 2012-05-14 2021-11-09 Biogen Idec Ma Inc. Lingo-2 antagonists for treatment of conditions involving motor neurons
WO2013175276A1 (en) 2012-05-23 2013-11-28 Argen-X B.V Il-6 binding molecules
BR112014029274B1 (pt) 2012-05-24 2022-02-15 Mountgate Innotech (Hk) Limited Anticorpo isolado, composição farmacêutica, uso do anticorpo, e, kit para tratar infecção rábica
US20150218238A1 (en) 2012-06-29 2015-08-06 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Resear Treating diseases by modulating a specific isoform of mkl1
US20150184154A1 (en) 2012-07-05 2015-07-02 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Resear New treatment for neurodegenerative diseases
WO2014006115A1 (en) 2012-07-06 2014-01-09 Novartis Ag Combination of a phosphoinositide 3-kinase inhibitor and an inhibitor of the il-8/cxcr interaction
KR102134088B1 (ko) 2012-08-24 2020-07-14 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 Ror1 암을 치료하고 전이를 저해하는데 이용을 위한 항체와 백신
MX2015008024A (es) 2012-12-21 2016-08-08 Biogen Int Neuroscience Gmbh Anticuerpos anti-tau humanos.
EP3517545A1 (en) 2012-12-31 2019-07-31 Neurimmune Holding AG Recombinant human antibodies for therapy and prevention of polyomavirus-related diseases
US20160002325A1 (en) 2013-03-08 2016-01-07 Vaccinex, Inc. Anti-cxcl13 antibodies and associated epitope sequences
US9920377B2 (en) 2013-03-15 2018-03-20 Sutter West Bay Hospitals FALZ for use as a target for therapies to treat cancer
JP6824735B2 (ja) 2013-06-06 2021-02-03 ピエール、ファーブル、メディカマン 抗Ｃ１０ｏｒｆ５４抗体およびその使用方法
ES2761587T3 (es) 2013-08-07 2020-05-20 Friedrich Miescher Institute For Biomedical Res Nuevo método de cribado para el tratamiento de la ataxia de Friedreich
TN2016000048A1 (en) 2013-08-13 2017-07-05 Sanofi Sa Antibodies to plasminogen activator inhibitor-1 (pai-1) and uses thereof
TW201722994A (zh) 2013-08-13 2017-07-01 賽諾菲公司 胞漿素原活化素抑制劑-１（ｐａｉ-１）之抗體及其用途
CN105611938A (zh) 2013-10-24 2016-05-25 免疫医疗有限责任公司 稳定的水性抗体配制品
WO2015127351A1 (en) 2014-02-24 2015-08-27 Celgene Corporation Methods of using an activator of cereblon for neural cell expansion and the treatment of central nervous system disorders
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
JP6640181B2 (ja) 2014-03-21 2020-02-05 エックス−ボディ インコーポレイテッド 二重特異性抗原結合ポリペプチド
EP3126397B1 (en) 2014-04-04 2020-01-29 Bionomics, Inc. Humanized antibodies that bind lgr5
WO2015189816A1 (en) 2014-06-13 2015-12-17 Friedrich Miescher Institute For Biomedical Research New treatment against influenza virus
EP3157535A1 (en) 2014-06-23 2017-04-26 Friedrich Miescher Institute for Biomedical Research Methods for triggering de novo formation of heterochromatin and or epigenetic silencing with small rnas
WO2016001830A1 (en) 2014-07-01 2016-01-07 Friedrich Miescher Institute For Biomedical Research Combination of a brafv600e inhibitor and mertk inhibitor to treat melanoma
WO2016046768A1 (en) 2014-09-24 2016-03-31 Friedrich Miescher Institute For Biomedical Research Lats and breast cancer
BR112017006598A2 (pt) 2014-09-30 2018-04-17 Neurimmune Holding Ag anticorpo de repetições antidipeptídeo derivado de ser humano (dprs)
EP3212510B1 (en) 2014-10-31 2020-12-09 Medlmmune, LLC Manufacturing method of a degassed composition
DK3229838T3 (da) 2014-12-11 2020-10-19 Pf Medicament Anti-C10orf54-antistoffer og anvendelser deraf
MX2017009038A (es) 2015-01-08 2017-10-25 Biogen Ma Inc Antagonistas de proteina 1 de interacción con el receptor de nogo que contiene el dominio de inmunoglobulina y repeticiones ricas en leucina (lingo-1) y usos para el tratamiento de trastornos desmielinizantes.
DE112016001013T5 (de) 2015-03-03 2017-12-21 Kymab Limited Antikörper, verwendungen und verfahren
EP3733701A1 (en) 2015-03-31 2020-11-04 MedImmune Limited A novel il33 form, mutated forms of il33, antibodies, assays and methods of using the same
AU2016323153B2 (en) 2015-09-15 2021-04-22 Board Of Regents, The University Of Texas System T-cell receptor (TCR)-binding antibodies and uses thereof
EP3368566A1 (en) 2015-10-28 2018-09-05 Friedrich Miescher Institute for Biomedical Research Tenascin-w and biliary tract cancers
US10472422B2 (en) 2016-01-08 2019-11-12 Abgenomics International Inc. Tetravalent anti-PSGL-1 antibodies and uses thereof
KR102603010B1 (ko) 2016-03-10 2023-11-16 비엘라 바이오, 인크. Ilt7 결합 분자 및 이의 사용 방법
AU2017239038A1 (en) 2016-03-22 2018-10-04 Bionomics Inc Administration of an anti-LGR5 monoclonal antibody
JP2018035137A (ja) 2016-07-13 2018-03-08 マブイミューン ダイアグノスティックス エイジーＭａｂｉｍｍｕｎｅ Ｄｉａｇｎｏｓｔｉｃｓ Ａｇ 新規な抗線維芽細胞活性化タンパク質（ｆａｐ）結合薬剤およびその使用
US11779604B2 (en) 2016-11-03 2023-10-10 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses and methods
SG11201909466RA (en) 2017-05-05 2019-11-28 Vaccinex Inc Human anti-semaphorin 4d antibody
CN111587123A (zh) 2017-11-09 2020-08-25 品通治疗有限公司 用于生成和使用人源化构象特异性磷酸化的τ抗体的方法和组合物
JP7165193B2 (ja) 2017-11-27 2022-11-02 パーデュー、ファーマ、リミテッド、パートナーシップ ヒト組織因子を標的とするヒト化抗体
TW202016144A (zh) 2018-06-21 2020-05-01 日商第一三共股份有限公司 包括cd3抗原結合片段之組成物及其用途
JP2022520088A (ja) 2019-02-13 2022-03-28 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド 抗末梢リンパ節アドレッシン抗体およびその使用
WO2020206063A1 (en) 2019-04-03 2020-10-08 Genzyme Corporation Anti-alpha beta tcr binding polypeptides with reduced fragmentation
KR20220012894A (ko) 2019-05-24 2022-02-04 사노피 전신 경화증의 치료 방법
WO2021202463A1 (en) 2020-03-30 2021-10-07 Danisco Us Inc Anti-rsv antibodies
EP4229081A1 (en) 2020-10-15 2023-08-23 The United States of America, as represented by The Secretary, Department of Health and Human Services Antibody specific for sars-cov-2 receptor binding domain and therapeutic methods
WO2022087274A1 (en) 2020-10-21 2022-04-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibodies that neutralize type-i interferon (ifn) activity
US20240115721A1 (en) 2021-01-13 2024-04-11 Memorial Sloan Kettering Cancer Center Anti-dll3 antibody-drug conjugate
CN117425501A (zh) 2021-01-13 2024-01-19 纪念斯隆凯特琳癌症中心 抗体-吡咯并苯二氮䓬衍生物缀合物
CA3209052A1 (en) 2021-02-19 2022-08-25 Rafael Cristian CASELLAS Single domain antibodies that neutralize sars-cov-2

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1564666A (en) * 1978-05-31 1980-04-10 Ng Mun Hon Heterocomplexes of interferon with immunoglobulin and pharmaceutical compositions thereof
GB2148299B (en) * 1983-09-01 1988-01-06 Hybritech Inc Antibody compositions of therapeutic agents having an extended serum half-life
US4703004A (en) * 1984-01-24 1987-10-27 Immunex Corporation Synthesis of protein with an identification peptide
US4590071A (en) * 1984-09-25 1986-05-20 Xoma Corporation Human melanoma specific immunotoxins
DE3585778D1 (de) * 1984-12-05 1992-05-07 Salk Inst For Biological Studi Monoklonaler antikoerper, spezifisch fuer brustkrebszelloberflaechenantigen.
NO881077L (no) * 1987-03-11 1988-09-12 Univ Michigan Kjemo-radio-immuno-konjugater.
DE3879395T2 (de) * 1987-05-29 1993-06-24 Sagami Chem Res Fusionsprotein, enthaltend lymphotoxin.
PH26813A (en) * 1987-09-02 1992-11-05 Ciba Geigy Ag Conjugates of cytokines with immunoglobulins
CA1329119C (en) * 1988-03-29 1994-05-03 Milton David Goldenberg Cytotoxic therapy
IE62463B1 (en) * 1988-07-07 1995-02-08 Res Dev Foundation Immunoconjugates for cancer diagnosis and therapy

Also Published As

Publication number Publication date
IL94167A (en) 1997-02-18
DE69005352T2 (de) 1994-04-14
HK1006678A1 (en) 1999-03-12
DK0396387T3 (da) 1994-02-14
JPH02306923A (ja) 1990-12-20
KR0181294B1 (ko) 1999-03-20
NO901986D0 (no) 1990-05-04
PT93966B (pt) 1996-12-31
NO301168B1 (no) 1997-09-22
JP3589459B2 (ja) 2004-11-17
NZ233413A (en) 1992-05-26
CA2015060C (en) 2008-03-18
ATE98873T1 (de) 1994-01-15
EP0396387B1 (en) 1993-12-22
ES2060947T3 (es) 1994-12-01
AU5379590A (en) 1990-11-08
FI902245A0 (fi) 1990-05-04
EP0396387A2 (en) 1990-11-07
PT93966A (pt) 1991-02-08
NO901986L (no) 1990-11-06
IE901405L (en) 1990-11-05
ZA902949B (en) 1992-02-26
DE69005352D1 (de) 1994-02-03
SA90110099B1 (ar) 2004-02-15
EP0396387A3 (en) 1991-04-03
FI100092B (fi) 1997-09-30
AU645747B2 (en) 1994-01-27
IE63847B1 (en) 1995-06-14
IL94167A0 (en) 1991-01-31
CA2015060A1 (en) 1990-11-05
CN1047035A (zh) 1990-11-21
CN1072505C (zh) 2001-10-10

Similar Documents

Publication Publication Date Title
KR900017612A (ko) 생물학적 반응 변경인자용 항체 수송 시스템
Yoshizaki et al. Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman's disease
Seckinger et al. Characterization of a tumor necrosis factor alpha (TNF-alpha) inhibitor: evidence of immunological cross-reactivity with the TNF receptor.
Vazquez-Lombardi et al. Molecular engineering of therapeutic cytokines
EP0367166A1 (en) Modified interleukin-2 and production thereof
Valiante et al. Role of the production of natural killer cell stimulatory factor (NKSF/IL-12) in the ability of B cell lines to stimulate T and NK cell proliferation
KR950700989A (ko) 사람 수지상 세포의 시험관내 생성방법 및 이의 용도(In vitro generation of human dendritic cells and uses thereof)
RU2005119305A (ru) Гуманизированное антитело (н14.18) на основании антитела 14.18 мыши, связывающееся с gd2, и его слияние с il-2
CA2348954A1 (en) A pharmaceutical composition for treating immune diseases
CA2104958A1 (en) Use of cell surface receptor targeted molecules for the treatment of viral diseases
Belsito et al. Enhancement by various cytokines or 2-beta-mercaptoethanol of Ia antigen expression on Langerhans cells in skin from normal aged and young mice. Effect of cyclosporine A.
AU621046B2 (en) Method for therapy of leukemias and certain other malignancies
Keegan et al. Superinduction of the murine B cell Fc epsilon RII by T helper cell clones. Role of IL-4.
HUT62932A (en) Process for producing pharmaceutical compositions comprising thioredoxin
US5932427A (en) In vitro assay system for identifying compositions useful for stimulating B cells
KR100225322B1 (ko) 종양괴사인자와 인터루킨-4의 상승작용 조성물
Doherty et al. Abnormal expression of interleukin-23 in mycosis fungoides/Sézary syndrome lesions
Palladino Jr et al. Immunopharmacology of tumor necrosis factors α and β
Saxena et al. Natural Killer—Resistance Inducing Factor (NK-RIF): A novel immunomodulatory cytokine
Higgins et al. Interleukin-1 Inhibitors and Their Significance in Rheumatoid Arthritis
Naujokas Cytokine regulation of freshly isolated IL-4-producing T lymphocytes
Dao et al. Interleukin-2 production by T cells: A study of the immunoregulatory actions of interferon-α, interferon-γ, and tumor necrosis factor-α in phenotypically different T cell clones
SILBERSTEIN et al. The ability of mouse monoclonal antibodies to direct the cytotoxic function of cytokine-activated human eosinophils
AU705327B2 (en) Use of cell surface receptor targeted molecules for the treatment of viral diseases
Ventura et al. Eosinophils in allergic diseases: Immuno-pharmacological regulation

Legal Events

Date Code Title Description
A201 Request for examination
AMND Amendment
E902 Notification of reason for refusal
AMND Amendment
E601 Decision to refuse application
J201 Request for trial against refusal decision
B701 Decision to grant
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20081204

Year of fee payment: 11

LAPS Lapse due to unpaid annual fee